Italia markets close in 8 hours 11 minutes

Orion Oyj (0M2N.L)

LSE - LSE Prezzo differito. Valuta in EUR.
Aggiungi a watchlist
48,55-0,49 (-1,01%)
Al 05:36PM GMT. Mercato aperto.

Orion Oyj

Orionintie 1A
Espoo 02200
Finland
358 10 4261
https://www.orion.fi

Settore/i
Settore
Impiegati a tempo pieno3.527

Figure dirigenziali chiave

NomeTitoloRetribuzioneEsercitateAnno di nascita
Mr. Timo LappalainenAdvisor1,72MN/D1962
Dr. Liisa HurmePres, CEO & Chairman of Exec. Management BoardN/DN/D1967
Mr. Jari Karlson M.Sc., M.Sc. (Econ.)CFO, Sr. VP of Animal Health & Member of the Exec. Management BoardN/DN/D1961
Mr. Olli Huotari Ll.M.Sr. VP of Corp. Functions, Gen. Counsel, Sec. & Member of Exec. Management BoardN/DN/D1966
Ms. Satu Ahomäki M.Sc., M.Sc. (Econ.)Sr. VP of Generics and Consumer Health Bus. Division & Member of the Exe. Mgmt. BoardN/DN/D1966
Ms. Virve Laitinen M.Sc. (Tech.), MBASr. VP of Corp. Strategy and Program Mgmt. Grp. Level Function & Member of the Exe. Mgmt. BoardN/DN/D1972
Prof. Outi Vaarala M.D., Ph.D.Sr. VP of Innovative Medicines, Sr. VP of R&D and Member of the Exe. Mgmt. BoardN/DN/D1962
Mr. Juhani KankaanpaaSr. VP of Global Operations & Member of Exec. Management BoardN/DN/DN/D
Mr. Niclas Lindstedt EMBA, M.Sc.Sr. VP of Animal Health Bus. Division & Member of the Exe. Mgmt. BoardN/DN/DN/D
Mr. Hao Pan M.Sc.Sr. VP of the Branded Products Bus. Division & Member of the Exe. Mgmt. BoardN/DN/D1971
Gli importi risalgono al giorno 31 dicembre 2021 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in EUR.

Descrizione

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, other European countries, North America, and internationally. It provides prescription drugs and self-care products, including Nubeqa for the treatment of prostate cancer; dexdor and Precedex for intensive care sedative; Stalevo and Comtess/Comtan for Parkinson's disease; Simdax for acute decompensated heart failure; and Fareston for breast cancer, as well as Salmeterol/fluticasone Easyhaler, Budesonide/formoterol Easyhaler, Formoterol Easyhaler, Budesonide Easyhaler, Beclomet Easyhaler, and Buventol Easyhaler drugs for the treatment of asthma and chronic obstructive pulmonary disease. The company also offers veterinary drugs comprising Bonqat, Clevor, Domosedan, Domitor, Antisedan, Dexdomitor, Domosedan Gel, Sileo, and Tessie; and APIs for generic and proprietary drugs, as well as provides contract manufacturing services. In addition, it markets and sells veterinary drugs manufactured by other international companies. The company serves various healthcare service providers and professionals, such as specialist and general practitioners, veterinarians, pharmacies, hospitals, healthcare centers, clinics, and laboratories, as well as consumers with pets. Orion Oyj has partnership with Propeller Health to connect the Easyhaler(R) product portfolio for the treatment of asthma and COPD; and a research collaboration and license agreement with Alligator Bioscience AB (publ) to discover and develop new bispecific antibody cancer therapeutics. Orion Oyj was founded in 1917 and is headquartered in Espoo, Finland.

Governance aziendale

L'ISS Governance QualityScore di Orion Oyj al 1 febbraio 2023 è 2. I criteri di valutazione fondamentali sono revisione: 3; Consiglio di Amministrazione: 2; diritti degli azionisti: 10; retribuzione: 3.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.